Navigation Links
Clearance of hepatitis C viral infection after liver transplantation
Date:8/29/2007

Touching stories of living donor transplantation are continuously happening in hospitals. One of these stories is reported recently in the August 14 issue of the World Journal of Gastroenterology because of its shining significance in hepatology. This article is going to bring comfort to many families.

It is about a desperate patient brought to Dr. Tatsuki Ichikawa in the Nagasaki University Hospital, Japan in 2004. This patient was quite a challenge for Dr Ichikawa. She was 60 years old with liver cirrhosis (LC) and liver cancer caused by hepatitis C virus (HCV); she had been diagnosed diabetic since 1995; and previous chemotherapies aiming to remove cancer did not bring any satisfactory result.

To free the patient from the severely damaged liver, liver transplantation (LT) was considered by Dr. Ichikawa when a loving daughter of the patient decided to donate part of her liver to her mother. However, one possibility that concerned Dr. Ichikawa most was that the explanted liver would get re-infected and progress rapidly to LC, since previous data indicated that complete clearance of HCV is the prerequisite for patients to have a good outcome. To minimize this possibility, patients were traditionally treated with interferon (IFN) and/or ribavirin before LT.

Trying to save the life of the patient, Dr Ichikawa decided to introduce the more powerful medicine, PEGylated IFN, in the treatment before liver transplantation. PEGylation is a chemical modification incurring higher water-solubility and higher stability to the modified polypeptide medicine. Five weeks after the PEG-IFN treatment, HCV antigen was no longer detectable from the patient serum, but HCV-RNA persisted. Even after the long treatment for 18 weeks, HCV RNA was still detectable. Since the complete clearance of HCV RNA seemed impossible, the liver transplantation was performed.

Unexpectedly and excitingly, clearance of HCV RNA was achieved just one month after the successful liver transplantation and HCV was never detected in this patient thereafter. Thus, this is the first reported case in which a complete recovery from HCV infection was achieved after LT, with a patient who was diagnosed positive in HCV-RNA and negative in HCV core antigen before LT. Dr. Ichikawa suggested that the long acting of PEG-IFN might bring good outcome to similar patients awaiting liver transplantation.

This case no doubt brings promising future for many LC patients. Due to the high percentage of HCV infected population in the world and unavailability of commercial vaccine against HCV, the case reported by Dr Ichikawa surely worth the attention of both doctors and common people.


'/>"/>
Contact: Lixin Zhu
wjg@wjgnet.com
0086-108-538-1892
World Journal of Gastroenterology
Source:Eurekalert

Related biology news :

1. Scientists Replicate Hepatitis C Virus in Laboratory
2. Norovirus, AIDS vaccine and Hepatitis Virus
3. Owl genomics presents a HEPATOCHIP for diagnosis of non-alcoholic steatohepatitis
4. UCLA study assesses cost-effectiveness of Hepatitis B drugs
5. Natural Killers Could Lead to New Hepatitis Treatments
6. FDA Approves New Treatment for Chronic Hepatitis B
7. Scalpel-free surgery could reduce risk of HIV and hepatitis exposure for health care workers
8. Identification of specific genes predicts which patients will respond to Hepatitis C treatment
9. Hepatitis C responds best to combo of ribavirin and interferon, study concludes
10. Researchers create infectious hepatitis C virus in a test tube
11. Use of high hydrostatic pressure to inactivate Hepatitis A virus in oysters studied
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/7/2017)... England , March 7, 2017 Brandwatch , ... chosen by The Prince,s Trust to uncover insights to ... across The Trust. The UK,s leading youth charity will ... social campaign results and get a better understanding of the topics ... ...
(Date:3/6/2017)... SAN MATEO, Calif. , March 6, 2017 ... predictive marketing and sales technology, today announced Predictive ... (AI) solution for infusing actionable sales intelligence into ... customers to automatically enable their sales organizations with ... contextual messages that allow for intelligent engagement. Predictive ...
(Date:3/2/2017)... March 2, 2017 Summary This ... understand Merck KGaA and its partnering interests and activities ... Description The Partnering Deals and Alliance since ... activity of one of the world,s leading life sciences ... upon purchase to ensure inclusion of the most up ...
Breaking Biology News(10 mins):
(Date:3/30/2017)... 30, 2017 Personal Genome Diagnostics Inc. (PGDx) today ... American Association for Cancer Research (AACR) Annual Meeting 2017, being ... D.C.  The company also announced that five scientists associated with ... th Annual AACR Team Science Award. ... Doug Ward , ...
(Date:3/29/2017)... KING OF PRUSSIA, Pa. , March 29, 2017 ... access to care, which is why CSL Behring awards ... advocacy work of rare disease patient groups. These groups ... patients, voices are heard on Capitol Hill and in ... current funding cycle, the community-based grant was awarded to ...
(Date:3/29/2017)... March 29, 2017 "Surging application of gesture ... the government are expected to drive the growth of ... gesture recognition market is expected to be worth USD ... 29.63% between 2017 and 2022. The touchless sensing market ... 2022, growing at a CAGR of 17.44% between 2017 ...
(Date:3/29/2017)... and PETACH TIKVAH, ... -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a ... for neurodegenerative diseases, announced financial results for ... "2016 was a highly successful and ... achievements and significant progress made on clinical, ...
Breaking Biology Technology: